Scienmag

JUNE 15, 2021

Responsibility for the safety, integrity and scientific validity of the trials fell to 12 experts of the COVID-19 Vaccine Data and Safety Monitoring Board, who now have taken the unusual step of publishing details of their review process Credit: UAB BIRMINGHAM, Ala.

Vaccination 77

Vaccination Vaccine Trials Clinical Trials 77

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

JUNE 27, 2021

Study points towards role of gut microbiome in vaccine effectiveness Credit: Image by Dr. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. The first human trial has shown no obvious side effects and a good immune response.

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

Scienmag

OCTOBER 5, 2020

Michael Houghton discovered hepatitis C virus and now is developing a vaccine Credit: Photo: Michael Holly Michael Houghton was awarded the 2020 Nobel Prize in Physiology or Medicine today in recognition of his discovery of the hepatitis C (HCV) virus.

Medicine 86

Medicine Vaccination Vaccine Development 86

Scienmag

OCTOBER 14, 2020

A prospective observational study testing the concept of trained immunity for protection from severe COVID-19 reported milder symptoms in COVID patients receiving MMR vaccination, as published in Allergy. Yet what if an existing vaccine […].

Vaccination 59

Vaccination Vaccine Allergies Clinical Trials 59

Scienmag

SEPTEMBER 8, 2020

September 9, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI) announced today that the Bill & Melinda Gates Foundation awarded close to 1.5 Following successful completion […].

Clinical Trials 45

Clinical Trials Clinical Trials Trials Vaccination 45

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Scienmag

NOVEMBER 18, 2020

Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group Peer-reviewed / Randomised Controlled Trial / People **There will be a UK Science Media Centre briefing at 10.15am UK time on Thursday 19th November about this study. […].

Immune Response 74

Immune Response Vaccination Vaccine Trials 74

Scienmag

OCTOBER 11, 2020

A largescale global trial designed to test the theory that the widely-used BCG vaccine could help protect against COVID-19 will soon recruit healthcare staff and care home workers in the UK.

Vaccination 81

Vaccination Vaccine Trials Allergies 81

Scienmag

JULY 23, 2021

Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract Credit: UAB BIRMINGHAM, Ala. and Troy Randall, Ph.D., write […].

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. The two drugs combined with radiation cleared the brain metastases in 75% of the animals, as reported in the journal Science Translational Medicine.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Scienmag

NOVEMBER 4, 2020

The finding provides a surrogate for testing the effectiveness of vaccine candidates Credit: Jennifer Jenks, Duke University School of Medicine DURHAM, N.C.

Vaccination 63

Vaccination Vaccine Research Development 63

Scienmag

SEPTEMBER 4, 2020

The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part vaccine.

Vaccination 45

Vaccination Vaccine Trials Antibody 45

The Pharma Data

MARCH 22, 2021

79% vaccine efficacy at preventing symptomatic COVID-19. The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo.

Trials 52

Trials Vaccination Vaccine Radiology 52

Scienmag

NOVEMBER 17, 2020

Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged 18-59 years recruited in China between 16 April and 5 May 2020 Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged (..)

Immune Response 70

Immune Response Vaccination Vaccine Trials 70

Drug Discovery World

NOVEMBER 2, 2022

The findings were published in The New England Journal of Medicine and presented at the American Society of Tropical Medicine & Hygiene 2022 Annual Meeting in Seattle. . “We The Phase II NIAID-USTTB trial evaluated a one-time, intravenous infusion of a monoclonal antibody called CIS43LS. . Trials in more potent antibody.

Antibody 52

Antibody Allergies Trials Medicine 52

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccination 52

Vaccination Vaccine Allergies Genome 52

Scienmag

DECEMBER 8, 2020

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalisations or severe disease reported in the COVID-19 vaccine group so far First clinical efficacy results of the vaccine are based on a pre-specified pooled (..)

Vaccination 41

Vaccination Vaccine Trials Clinical Trials 41

Scienmag

OCTOBER 15, 2020

Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate was carried out in China between 29 April and 30 July 2020 and involved more than 600 healthy volunteers.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

pharmaphorum

JULY 28, 2022

Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year earnings forecasts. Development in peanut allergy has also been discontinued, said Sanofi in its second-quarter update. Vaccine sales climbed 15% to €1.8

Sales 59

Sales Allergies Vaccination Vaccine 59

Scienmag

APRIL 10, 2021

[link] New York, NY (April 10, 2021) – A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase (..)

Vaccination 67

Vaccination Vaccine Development Clinical Trials 67

Pfizer

JULY 19, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. 1 as compared to the companies’ current COVID-19 vaccine.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Drug Discovery World

JANUARY 21, 2024

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Protein 52

Protein Vaccination Vaccine Development 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 .–(BUSINESS WIRE)–Dec. 8, 2020– Moderna, Inc.,

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” . PLYMOUTH MEETING, Pa. ,

DNA 40

DNA Vaccination Vaccine Immune Response 40

Scienmag

MARCH 10, 2021

Now, real world data on vaccinations among employees at Mass […].

Vaccination 48

Vaccination Vaccine Clinical Trials Clinical Trials 48

The Pharma Data

NOVEMBER 16, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Scienmag

JUNE 10, 2021

National Comprehensive Cancer Network’s patient information team provides a patient and caregiver version of recently updated, evidence-based expert consensus recommendations for vaccinating people with cancer against COVID-19 PLYMOUTH MEETING, PA [June 10, 2021] — The National Comprehensive Cancer Network® (NCCN®) today announced the publication (..)

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

Scienmag

NOVEMBER 30, 2020

– The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, has been re-funded for the next seven years by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and collaborating NIH Institutes. Los Angeles, Calif. M.Sc, […].

Allergies 41

Allergies Clinical Trials Clinical Trials Trials 41

Scienmag

JANUARY 11, 2021

Scientists reach new milestone in vaccine development for neglected tropical disease Researchers have taken an important step forward in developing a controlled human infection model to test leishmaniasis vaccines.

Scientist 40

Scientist Vaccination Vaccine Development 40

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. This new study will complement Mymetics’ other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.

Vaccination 40

Vaccination Vaccine Containment Immune Response 40

Scienmag

SEPTEMBER 30, 2020

Age and underlying health conditions also associated with decreased survival Credit: Justin Kelley Clinical trials are testing whether medications that treat human immunodeficiency virus (HIV) can also treat COVID-19, leading some patients with HIV to believe they might be protected against the coronavirus.

Clinical Trials 94

Clinical Trials Clinical Trials Medicine Trials 94

The Pharma Data

MARCH 24, 2021

76% vaccine efficacy against symptomatic COVID-19. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. D8110C00001 1.

Radiology 52

Radiology Vaccination Vaccine Trials 52

pharmaphorum

SEPTEMBER 29, 2022

Dupixent (dupilumab) has been approved on the back of two phase 3 trials in patients with prurigo nodularis whose symptoms were inadequately controlled with current drugs. “With this approval, those suffering with prurigo nodularis finally have a medicine to address the debilitating signs and symptoms of the disease,” he added.

Drugs 69

Drugs Immune Response Allergies Sales 69

XTalks

DECEMBER 20, 2023

The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy. Bayer’s Astepro (azelastine), an over-the-counter medication for cold, flu and allergies, led the pack in the first half of 2023 with 7.4 billion ad impressions.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59